Gimme Care GLP-1 health data tracking lawsuit (Maddocks v. Start Gimme)

A customer of Gimme Care, an online seller of compounded GLP-1 weight-loss drugs and other peptide therapies, has sued the company over how its website handles health information. James Maddocks says the site sent his treatment choice, intake answers and contact details to advertising companies through tracking code he was never told about.

The case is Maddocks v. Start Gimme, LLC d/b/a Gimme Care, No. 8:26-cv-03195, filed October 21, 2026, in the U.S. District Court for the Middle District of Florida in Tampa. It is a proposed class action. No court has ruled, no class has been certified and there is no settlement.

Start Gimme, LLC is a Delaware company that does business as Gimme Care and runs gimme.care and its intake site, intake.gimme.care. The complaint says it was formed in May 2025 and sells compounded GLP-1 drugs, sermorelin, NAD+ and glutathione after a licensed provider reviews an online questionnaire. It says the company fills Florida orders through a Florida-licensed compounding pharmacy.

Maddocks lives in New Port Richey in Pasco County, Florida. He is represented by Almeida Law Group.

According to the complaint, Maddocks used the website around March 2026 to get compounded tirzepatide for weight loss. He viewed the treatment page, clicked "Get started" and completed the medical intake questionnaire. He says he disclosed his weight-loss goal, height and weight, current medications, prior GLP-1 use and medical history by clicking answer buttons. He then entered his email and phone number, bought the drug with his name, birth date and addresses, and received it after a contracted provider approved the request.

The complaint says the site runs the Meta Pixel, TikTok Pixel, Reddit Pixel, Criteo OneTag and Microsoft UET tag, including on the intake questionnaire and checkout. It alleges these tools captured in real time the pages he viewed, the text of the answer buttons he clicked and his contact details, and sent them to those companies. It also alleges that hashed versions of his email, phone number and name were sent so the platforms could match his activity to his accounts.

The complaint says users are not asked to accept a privacy policy or terms before tracking starts on the home page, and that terms and privacy links appear only at checkout.

Maddocks says Gimme Care told users their health answers would stay between them, the company and the reviewing provider, and instead shared them with advertisers. He says the company was on notice from federal regulators' earlier actions against telehealth firms over tracking pixels, including a July 2023 joint warning from the FTC and the federal health privacy office to 130 hospital systems and telehealth providers. These are allegations.

He brings five claims:

• Violation of the federal Electronic Communications Privacy Act, for the nationwide class.
• Violation of the Florida Security of Communications Act, for the Florida subclass.
• Violation of the Florida Deceptive and Unfair Trade Practices Act, for the Florida subclass.
• Intrusion upon seclusion, for the Florida subclass.
• Unjust enrichment, for the nationwide class.

We found no response from Gimme Care in court or in public.

Nothing has been decided. The public docket shows the case is assigned to Judge James S. Moody Jr., with Magistrate Judge Amanda Sansone. The court has not ruled on whether the tracking happened, whether it was lawful or whether the case can proceed as a class action.

The complaint proposes two groups:

• Nationwide class: everyone in the United States who, during the class period, accessed the website and viewed information about, submitted an intake questionnaire about or bought a medication or treatment, and whose communications with the site were sent to third parties through the tracking tools.
• Florida subclass: members of the nationwide class who used the website while in Florida.

Excluded are the judges and their families, Gimme Care and its affiliates and their officers and directors, people who opt out, people whose claims were already decided or released, and counsel. The complaint estimates the class at tens of thousands of people. The class period is not given as specific dates.

1. Save order confirmations, questionnaire emails and account records from Gimme Care.
2. Write down roughly when you used the site, what treatments you looked at and where you were at the time, since the Florida subclass depends on location.
3. Review ad and privacy settings on Facebook, Instagram, TikTok, Reddit and Microsoft accounts if you are concerned about health-related ads.
4. Watch for a class notice if the case is certified or settles.

There is no payment now. For the nationwide class, the complaint seeks federal wiretap damages, which under 18 U.S.C. 2520 are the greater of actual damages plus profits or statutory damages of $100 a day or $10,000, at the court's discretion. For the Florida subclass, it seeks the greater of $100 a day or $1,000 under Fla. Stat. 934.10, plus punitive damages, and actual damages under the Florida consumer law.

It also asks for restitution of revenue from the alleged conduct, an order requiring notice and consent before tracking, and destruction of collected data by Gimme Care and its vendors. These are requests, not awards. Settlements usually pay less than the statutory maximums.

• May 2025: Start Gimme formed, per the complaint.
• Around March 2026: Maddocks used the site and bought tirzepatide.
• October 21, 2026: Complaint filed.

There are no claim, opt-out or objection deadlines yet.

• Tracking pixel: A small piece of code on a web page that reports visitor actions to another company.
• Compounded drug: A medication mixed by a pharmacy for patients, which is not an FDA-approved brand product.
• Wiretap law: A law that bars intercepting the contents of communications without consent.
• Intrusion upon seclusion: A privacy claim for a highly offensive intrusion into someone's private affairs.
• Unjust enrichment: A claim that a company kept a benefit it should return.

Gimme Care must be served and will then answer or move to dismiss. Companies in pixel tracking cases often argue that users consented through privacy policies or that the federal wiretap law allows a party to a communication to share it. The court would decide those questions.

This article relies on the complaint, the court docket, 18 U.S.C. 2520 and Fla. Stat. 934.10. Descriptions of the trackers and the data they sent come from the complaint, which includes the plaintiff's analysis of the site. We did not test the website. The company's formation date and pharmacy arrangements are as stated in the complaint.

Class Action Pulse is not a law firm or settlement administrator and does not guarantee eligibility or payment. This article is general information, not legal advice.